11 Mar 2026 by admin in UncategorizedComments Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
23 Feb 2026 by admin in UncategorizedComments Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
11 Feb 2026 by admin in UncategorizedComments Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
09 Feb 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
05 Jan 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
21 Dec 2025 by admin in UncategorizedComments Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
15 Dec 2025 by admin in UncategorizedComments Zenas BioPharma’s Partner, InoCare Pharma, Anounces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
